Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cysteine desulfurase (NFS1)–LYR motif-containing protein 4 (ISD11)–Mitochondrial acyl carrier protein (ACP)–Iron-sulfur cluster assembly enzyme (ISCU) complex is the primary enzymatic machinery responsible for the de novo biosynthesis of iron-sulfur (Fe-S) clusters in human mitochondria (Source: UniProt P56279, Q9H1K1). Within this complex, NFS1 functions as a cysteine desulfurase that extracts sulfur from L-cysteine, while ISCU acts as the scaffold upon which the [2Fe-2S] cluster is initially built (Source: PubMed 29925948). The subunits ISD11 and the mitochondrial acyl carrier protein (ACP, also known as NDUFAB1) are essential for stabilizing NFS1 and regulating its catalytic activity (Source: PubMed 28562585). This complex is vital for the maturation of numerous Fe-S proteins involved in the respiratory chain, the tricarboxylic acid cycle, and DNA maintenance. Dysregulation of this complex is linked to several human diseases, most notably Friedreich's ataxia, which results from a deficiency in frataxin, a protein that binds to and activates this core complex (Source: PubMed 24634534). Additionally, certain cancers overexpress NFS1 to mitigate oxidative stress and prevent ferroptosis, positioning the complex as an emerging target for oncology therapeutics (Source: Nature 2017, 551(7682)). Experimental inhibitors targeting the sulfur-transfer mechanism are currently being explored to induce metabolic crisis in susceptible tumor cells.
Inhibition of the cysteine desulfurase activity of NFS1 or disruption of the protein-protein interactions between NFS1, ISD11, ACP, and ISCU to prevent the formation of iron-sulfur clusters, leading to mitochondrial dysfunction and cell death.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cysteine desulfurase (NFS1)–LYR motif-containing protein 4 (ISD11)–Mitochondrial acyl carrier protein (ACP)–Iron-sulfur cluster assembly enzyme (ISCU) complex (SDAI complex).